Get your full text copy in PDF
Lixun Guan, Xiaohong Li, Huaping Wei, Zhenyang Gu, Shasha Zhao, Chengying Zhu, Nan Yang, Feiyan Wang, Lan Luo, Zhe Gao, Wenrong Huang, Honghua Li, Quanshun Wang, Daihong Liu, Xiaoxiong Wu, Chunji Gao
(Department of Hematology, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China (mainland))
Ann Transplant 2018; 23:427-433
There is currently little information on haploidentical hematopoietic cell transplantation (haplo-HCT) for T-lymphoblastic lymphoma (T-LBL). Data about peripheral blood stem cells (PBSC) as a reliable graft source for T-LBL treatment are lacking.
MATERIAL AND METHODS: T-LBL patients who underwent T cell-replete haploidentical peripheral blood hematopoietic cell transplantation (haplo-PBHCT) from July 2007 to January 2017 were retrospectively evaluated.
RESULTS: A total of 25 patients (age ≥15 years) with median age of 24 (range 15–51) years were enrolled. The median number of CD34+ cells infused was 5.0 (1.6–14.4) 106/kg. Sustained myeloid engraftment with full donor chimerism was achieved in all patients. The cumulative incidence of grades 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 24%. Two-year extensive chronic GVHD cumulative incidence was 20%. The 3-year overall survival rate for all patients was 70%. The median survival time of the complete remission (CR) group was better than that of the non-CR group (not reached vs. 9 m) (P<0.01). The relapse rate was 17% for patients who obtained CR and were given haplo-HCT as consolidation treatment.
CONCLUSIONS: This study indicates that haplo-PBHCT is a safe and effective method for the treatment of T-LBL.